Interactive Investor

UK and global funds are the key drivers of our model portfolios

A year on from Pfizer Monday, funds focusing on developed market equities have served our models well.

16th November 2021 11:16

by Kyle Caldwell from interactive investor

Share on

A year on from Pfizer Monday, funds focusing on developed market equities have served our models well.

Global outlook 600 x 400

Over the past year, our five model portfolios returned between 23% and 28%, with Pfizer Monday (9 November 2020) helping to turbocharge returns, particularly for the UK and global fund constituents.

Leading the way is ii Active Income, up 27.8% over the past year. The three growth-focused portfolios follow, with respective returns of 26.9%, 26.6% and 25% for ii Active Growth, ii Low-Cost Growth and ii Ethical Growth. Trailing the pack, although not by much, is ii Low-Cost Income, up 23.2%.

Below, we drill down into performance over the past year, as well as examining how each portfolio fared in October. During the month, all five models produced positive returns, as markets recovered their poise. 

At the start of every quarter, the five portfolios are automatically rebalanced back to their target allocations. Our constituents have target allocations of either 5%, 10% or 15%. The weightings are displayed on our model portfolios page.

The Active Income, Active Growth and Ethical Growth portfolios have 10 constituents, which are all actively managed investment funds and trusts.

The Low-Cost Income and Low-Cost Growth models contain nine index-tracking funds or exchange-traded funds (ETFs).

Performance of models over 12-month time periods

Discrete returns for the periods*:
01/11/2020 - 31/10/202101/11/2019 - 30/10/202001/11/2018 - 30/10/2019
Growth portfolios
ii Active Growth26.913.9N/A
ii Ethical Growth2514.3N/A
ii Low-Cost Growth26.6-1.3N/A
Growth benchmark27.4-2.49.7
Income portfolios
ii Active Income27.8-13.8N/A
ii Low-Cost Income23.2-13.3N/A
Income benchmark27.6-157.8
Morningstar GBP Adventurous Allocation average24.1-0.98.6

Notes *as at 31 October 2021. Portfolio launch date (for monitoring purposes) was 1 January 2019, except Ethical Growth portfolio, launched 1 October 2019. Data source: Morningstar Direct. Past performance is not a reliable indicator of future results.

Income portfolios

In October, the income portfolios lagged the growth portfolios, which is to be expected given that it was a month during which markets were in recovery mode having posted losses in September. The S&P 500 index, for example, closed 4.8% down in September before going on to post its best monthly performance so far this year in October, racking up a gain of just over 7%. 

For the month, ii Active Income and ii Low-Cost Income returned 0.6% and 0.4%. 

The three top performers in ii Active Income were BMO Commercial Property Trust (LSE:BCPT), Bankers (LSE:BNKR) and Murray International (LSE:MYI), with gains of 6.7%, 3.8% and 2.2%. At the other end of the table, Utilico Emerging Markets (LSE:UEM) was a notable laggard; it declined by 4.6%.

Overall, emerging markets struggled in October. This was also reflected in ii Low-Cost Income, as the WisdomTree Emerging Markets Equity Income ETF was the worst performer, down 2.2%.

The rest of the portfolio’s constituents posted small gains. Two members stood out with the same return of 3.1% for Vanguard FTSE UK Equity Income Index and iShares Global Property Securities Equity Index.

Over the past year, the emerging market constituents in the two passive models have performed as well as, and better in some cases, than the developed market-focused funds. As we explain below, this does not play out in the three growth portfolios. Instead, emerging market growth funds have notably underperformed. 

Since 1 November 2020, in ii Active Income, Utilico Emerging Markets has gained 28.8%. This is comfortably ahead of three of the four global funds in the portfolio, which mainly stick to developed market equities. Over this period, Bankers, Morgan Stanley Global Brands Equity Income and Fidelity Global Dividend returned 18.6%, 18.1% and 17.9%.

The other global fund, Murray International (LSE:MYI), returned 27.8%, slightly behind Utilico Emerging Markets. Murray International has more than 40% of its assets in Asian and emerging market equities, which is much higher than a typical global fund or trust. Most tend to hold little in the region, or stick to developed markets.

The two UK members have performed even better. City of London (LSE:CTY) is up 32.6% and Man GLG Income Professional has returned 41.5%. Both have benefited from the UK dividend recovery. In addition, both favour value shares, which for several months performed well following the vaccine announcements and successful roll-outs.

The overall best performer in ii Active Income, is BMO Commercial Property Trust. Over the past year, its share price total return is 74.9%. The other alternative selection, Standard Life Private Equity, has also served the portfolio very well, with a gain of 61.1%.

It has been a roller-coaster ride for shareholders in BMO Commercial Property Trust.In the first quarter of 2020, its share price fell 35% and its discount to its net asset value (NAV) widened to more than 50%. This was in response to national lockdowns, which negatively impacted the trust's property holdings, including offices and retailers. Commercial property is a bellwether for the wider economy, so it is an economically sensitive asset class. 

Its share price remains below its pre-pandemic sell-off level – it was trading at 108p per share on 21 February 2020 and is currently trading at 102p (as at the time of writing) – but the share price has been climbing over the past year and its discount declining (helped by some share buybacks by the board) amid expectations that the outlook for property is brightening as the global economy recovers from the Covid-19 pandemic.

In ii Low-Cost Income, the WisdomTree Emerging Markets Equity Income ETF has returned 24.3% over the past year . This in line with our three developed market equity picks, which are up 29.5%, 26.8% and 22%: the Vanguard FTSE All World High Dividend Yield ETF, the SPDR® S&P Global Dividend Aristocrats ETF and the WisdomTree Global Equity Dividend Growth ETF.

The top overall performer over one year was Vanguard FTSE UK Equity Income Index, up 37.8%. It has benefited from the value rally, due to being heavily exposed to value sectors, such as banks, oil and miners.

In contrast, the SPDR® S&P UK Dividend Aristocrats ETF returned 22.8%. It seeks to invest in up to 40 stocks that have held or increased their dividends over the past seven years. Therefore, it has less exposure to the aforementioned value sectors, as many of those companies cut their dividends in response to the pandemic and have since returned to handing cash back to shareholders. 

% total return (with income reinvested) as of 31 October 2021, after:
1 month3 mths6 mths1 yearSince inception*
Income portfolios
ii Active Income0.61.33.427.825.4
ii Low-Cost Income0.41.84.223.218.7
Income benchmark0.92.53.227.620.4
Morningstar GBP Adventurous Allocation average12.34.324.138.9

Notes: *Portfolio launch date (for monitoring purposes) was 1 January 2019. Data source: Morningstar Direct. Past performance is not a reliable indicator of future results.

Growth portfolios

The ii Ethical Growth portfolio topped the performance charts in October, up 1.7%. The passive ii Low-Cost Growth returned 1.3%, while ii Active Growth gained 1%.

Syncona (LSE: SYNC) was by far the biggest contributor to returns. Its share price total return for the month was 18%. Over one, year, though, it is deep in the red, having lost 19.8%. Last week, the trust, which invests in life science companies, reported its six-month results to the end of September. For this period, its net asset value (the performance of its underlying investments) declined by 11.4%. The decline was driven predominantly by falls in the share price of two of the trust’s listed holdings: Freeline Therapeutics Holdings (NASDAQ:FRLN) and Achilles Therapeutics (NASDAQ:ACHL). Syncona attributes the falls to “operational challenges” and “market sentiment”.

Over the past year, in common with the income portfolios, UK and global funds have been the main performance drivers. Four funds in ii Ethical Growth have returned over 30%: Impax Environmental Markets (LSE:IEM), Baillie Gifford Positive Change, Liontrust UK Ethical 2 and Montanaro Better World. The respective returns were 41.6%, 38%, 34.8%, and 32.6%. Not too far behind, with a return of 29.8%, was Royal London Sustainable Leaders.

In ii Low-Cost Growth, there’s not much to note in October. Seven members posted small gains, while the other two were slightly in the red.

Over one year, the two UK and three developed equity passive picks returned over 30%. The top three performers are Vanguard Global Small-Cap Index, the Vanguard FTSE 250 UCITS ETF and Fidelity Index, with returns of 36.8%, 36.1% and 35.4%. Completing the top five with gains of 32.6% and 32.4% are the iShares Core MSCI World ETF and L&G Global 100 Index

The same trend played out for ii Active Growth. Since last November, the biggest performance drivers have been UK and global funds. The top three contributors have been Scottish Mortgage (LSE:SMT), Liontrust Special Situations and Fundsmith Equity, with gains of 51.4%, 31.9% and 23.3%.

The best performer was Standard Life Private Equity, up 61.1%. But as it only comprises 5% of the portfolio, it has less influence compared to other constituents.

In contrast to the income portfolios, the emerging market constituents in the three growth portfolios have notably lagged funds backing equities listed in developed markets – the US, Europe and the UK - over the past year. Stewart Investors Global Emerging Market Sustainability (ii Ethical Growth) returned 11.7%; Fidelity Index Emerging Markets gained 9.5% (ii Low-Cost Growth); and JP Morgan Emerging Markets (LSE:JMG) returned 12.7% (ii Active Growth).

% total return (with income reinvested) as of 31 October 2021, after:
1 month3 mths6 mths1 yearSince inception*
Growth portfolios
ii Active Growth13.56.226.966.2
ii Ethical Growth1.73.272540.9**
ii Low-Cost Growth1.33526.641.7
Growth benchmark2.33.76.327.442.1
Growth benchmark since 1 October 2019 (date ii Ethical Growth was launched)22.2**
Morningstar GBP Adventurous Allocation average12.34.324.138.9

Notes *as at 31 October 2021. Portfolio launch date (for monitoring purposes) was 1 January 2019, except **Ethical Growth portfolio, launched 1 October 2019. Data source: Morningstar Direct. Past performance is not a reliable indicator of future results.

Our Model Portfolios have been compiled by investment experts to help investors who do not have the time or the confidence to make their own investment choices. There are a variety of financial goals they are designed to help people meet.

However, you should note that the selection of our Model Portfolios is not a ‘personal recommendation’. This means we have not assessed your investment knowledge, your financial situation (including your ability to bear losses), your investment objectives, your risk tolerance, or your sustainability preferences.

You should ensure that any investment decisions you make are suitable for your personal circumstances, and if you are unsure about the suitability of a particular investment or think you need a personal recommendation, you should speak to a suitably qualified financial adviser.

The past performance of an investment is not a reliable indicator of future results, and ii does not guarantee or predict the future performance of the Model Portfolios or the constituent investments.

Risk Warning(s)

The value of your investments may go down as well as up. You may not get back all the money that you invest.

Investing in emerging markets involves different risks from developed markets, in many cases the risks are greater.

The value of international investments is affected by currency fluctuations which might reduce their value in sterling.

Disclosure(s)

Annual performance can be found on the factsheet of each fund, trust or ETF. Simply click on the asset’s name and then the performance tab.

Any changes to the Model Portfolio constituents and the rationale behind those decisions will be communicated through the Quarterly Investment Outlook.

To see a list of previous updates to Model Portfolio constituent investments, please go to the relevant Model Portfolio’s ‘Timeline’.

ii adheres to a strict code of conduct. Members of ii staff may have holdings in one or more Model Portfolios (or the constituent investments), which could create a conflict of interest. Any member of staff involved in the development of research about any financial instrument in which they have an interest are required to disclose such interest to ii. We will at all times consider whether such interest impairs the objectivity of the recommendation to add/remove a constituent investment to/from a Model Portfolio.

In addition, staff involved in compiling the Model Portfolios are subject to a personal account dealing restriction. This prevents them from placing a transaction in the specified instrument(s) for five working days before and after an investment is included or amended and made public within a Model Portfolio. This is to avoid personal interests conflicting with the interests of investors in the Model Portfolios and their constituent investments.

Get more news and expert articles direct to your inbox